XI Reunión. Estado del Arte en INSUFICIENCIA CARDIACA PRÁCTICA CLÍNICA Y MODELOS ORGANIZATIVOS

Sede: Hotel Meliá MaríaPita, A Coruña

A CORUÑA 27-28 SEPTIEMBRE 2024





XI Meeting. State of the Art in HEART FAILURE CLINICAL PRACTICE AND ORGANIZATIONAL MODELS

Venue: Hotel Meliá MaríaPita, A Coruña

A CORUÑA 27-28 SEPTEMBER 2024

Genetic testing: what to look for, when to do it and what it brings to clinical management.

Esteban Martín Álvarez | *Complexo Hospitalario Universitario A Coruña*













ACoruñaHF2024



WHAT TO LOOK FOR?






Figure 4. Positions of amino acids (highlighted in yellow) subjected to mutations described in Table 1. The figure was created through "www.rcsb.org" and "biorender.com" web sites (license agreement number KJ247URGZS), access date 22 June 2022.

- **Human TTR** is a protein encoded by a single gene located on chromosome 18q.
- Mature protein has 127 amino acids. Pro-TTR monomers have 147 amino acids (including a 20-amino acid signal peptide). The <u>current nomenclature</u>, according to the Human Gene Organization, <u>includes this peptide</u>.
- ATTRv is caused by pathogenic variants in the TTR gene that reduce stability of the TTR tetramer, leading to easier dissociation in pro-amyloidogenic monomers.





WHAT TO LOOK FOR?






A Coruña

Heart Failure Academy

8

ATTRv around the world

- Estimated **prevalence** of **1/1.000.000**.
- Endemic foci: Portugal (almost 1/500), Sweden, Brazil, Japan and 2 regions in Spain (Mallorca and Huelva).
- Typical phenotype for specific variants, but geographical area also matters.




p.Val142Ile

- Most frequent in USA y UK, mainly in people with black ancestry.
- Predominantly cardiac phenotype.

p.Val50Met

- Most common pathogenic variant worldwide
- Most frequent in Europe, South America and Japan.
- **Early-onset** phenotype in endemic areas in Japan and Portugal. **Late-onset** in the rest.



Porcari, Aldostefano et al. European journal of heart failure vol. 25,4 (2023): 515-524.



A CORUÑA HF 27-28 SEPTEMBER 2024

ATTRv in Spain

Mutaciones	
Val50Met	120 (67,8)
Val142Ile	22 (12,4)
Glu109Lys	14 (7,8)
Ser97Tyr	6 (3,4)
Val122Del	4 (2,2)
Ser43Asn	2 (1,1)
Asp38Asn	2 (1,1)
Val71Ala	1 (0,5)
Glu89Gln	1 (0,5)
Ala65Thr	1 (0,5)
Thr80Ala	1 (0,5)
Leu32Pro	1 (0,5)
Glu74Gln	1 (0,5)
Ala128Val	1 (0,5)



Downloaded from Asociación Balear de Enfermedad de Andrade

#ACORUÑAHF2024


The most frequent variant in **Spain** is **p.Val50Met**, not only in the two endemic areas, but in the others.

The typical form in Spain is the **late-onset phenotype** (vs Portugal).



WHEN TO DO A GENETIC TEST?


- As soon as **ATTR-CM** has been confirmed, the presence of **pathogenic variants** in the TTR gene should be evaluated and **genetic** counseling should be given.
- ATTRv and ATTRwt are two different diseases. 100% of ATTRwt affect the heart, but not all ATTRv do so (30-100%).
- Genetic testing should be done **regardless of age**.



A CORUÑA HF 27-28 SEPTEMBER 2024

Heart Failure

• Genetic testing should be done **regardless of age**.




- Overall, the prevalence of ATTRv among <u>300</u> patients with ATTR-CM was **12%**.
- In the cohort of ATTR-CM patients ≥ 70 years, 13/246 had ATTRv (5.3%).
- Prevalence of ATTRv among elderly female patients with ATTR-CM was 13%.
- Eldest ATTRv patient was 93-year-old Caucasian female with the p.Val142Ile variant.
- Prevalence in <60 years was 100%.
- Implications of ATTRv diagnosis: transthyretin-specific drug treatment, genetic screening in relatives, identification of asymptomatic carriers.

#ACORUÑAHF2024



A CORUÑA HF 27-28 SEPTEMBER 2024


RELEVANCE IN CLINICAL MANAGEMENT



Family Study and Asymptomatic Carriers of Pathogenic Variants

- In hereditary TTR amyloidosis, we do not see isolated patients, but families.
- The age of presentation, phenotype, penetrance, and **progression** depend on the particular variant.
- To decide when to initiate penetrance assessment in carriers, we are guided by the **specific variant** and the age of onset in affected relatives (PADO).

Phenotype group	Genotype	Penetrance	Typical age of onset	Rate of progression
Neurologic	V30M early onset	>90%	<40 years	++++++
Neurologic/mixed	V30M late onset	>60%	>50 years	++++++
Cardiac	V122I	Unknown	55 years	++
	L111M	>90%	35-40 years	++
	T60A	>90%	55 years	++
	168L	>90%	55 years	++
Mixed	S77Y	>90%	55 years	++++
	E89Q	>90%	50 years	++++
	G47E	>90%	30 years	++++++



A CORUÑA HF 27-28 SEPTEMBER 2024

AGE

-

Heart Failure

Academ


Typical age of onset for the specific genotype

Family history

#ACORUÑAHF2024

· Proband age of onset

Genetics are a must in ATTR!! CARRIERS PROGNOSIS DIAGNOSIS (ATTRv vs ATTRwt) GENETIC COUNSELING




Modified from García-Pavía P, et al. Eur Hear J. 2021;42:1554-1568.





A Coruña

Heart Failure Academy



¡MUCHAS GRACIAS POR LA ATENCIÓN!





Complexo Hospitalario Universitario A Coruña





